Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Becton Dickinson to invest $1.2B to expand capacity for PFS, ADDS » 07:06
12/02/20
12/02
07:06
12/02/20
07:06
BDX

Becton Dickinson

$238.60 /

+3.94 (+1.68%)

Becton Dickinson…

Becton Dickinson announced plans to invest approximately $1.2B over a four-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes, or PFS, and advanced drug delivery systems, or ADDS, across its six global manufacturing locations and add a new manufacturing facility in Europe. The new manufacturing facility in Europe is expected to be operational by the end of 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs. The six current manufacturing facilities for BD Pharmaceutical Systems that will see a portion of this investment include facilities in Columbus, Nebraska; Cuautitlan, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabanya, Hungary.

ShowHide Related Items >><<
BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

11/05/20 Piper Sandler
Becton Dickinson price target lowered to $275 from $296 at Piper Sandler
10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/02/20
Fly Intel: Top five analyst upgrades
BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

  • 21
    May
BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

Hot Stocks
Becton Dickinson to invest $1.2B in pre-fillable syringe manufacturing capacity » 07:06
12/02/20
12/02
07:06
12/02/20
07:06
BDX

Becton Dickinson

$238.60 /

+3.94 (+1.68%)

BD announced plans to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

11/05/20 Piper Sandler
Becton Dickinson price target lowered to $275 from $296 at Piper Sandler
10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/02/20
Fly Intel: Top five analyst upgrades
BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

  • 21
    May
BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

BDX Becton Dickinson
$238.60 /

+3.94 (+1.68%)

Conference/Events
Piper Sandler to hold a virtual conference » 04:55
12/02/20
12/02
04:55
12/02/20
04:55
ABMD

Abiomed

$268.45 /

-5.95 (-2.17%)

, ALBO

Albireo Pharma

$37.93 /

+0.72 (+1.93%)

, ALGN

Align Technology

$500.52 /

+18.81 (+3.90%)

, ALLO

Allogene Therapeutics

$31.91 /

+0.9 (+2.90%)

, ALPN

Alpine Immune Sciences

$9.64 /

-0.305 (-3.07%)

, ALT

Altimmune

$13.82 /

+1.63 (+13.37%)

, AMRN

Amarin

$4.92 /

-0.04 (-0.81%)

, APTX

Aptinyx

$3.55 /

-0.425 (-10.71%)

, BBI

Brickell Biotech

$0.64 /

-0.0289 (-4.31%)

, MASI

Masimo

$253.27 /

-1.38 (-0.54%)

, ZBH

Zimmer Biomet

$146.00 /

-3.175 (-2.13%)

, XNCR

Xencor

$41.36 /

-0.97 (-2.29%)

, VCRA

Vocera

$34.64 /

+0.87 (+2.58%)

, ICPT

Intercept

$35.69 /

+0.21 (+0.59%)

, IMV

IMV Inc.

$3.63 /

-0.23 (-5.96%)

, OTIC

Otonomy

$4.81 /

+0.345 (+7.73%)

, OMCL

Omnicell

$107.17 /

+2.4 (+2.29%)

, NRIX

Nurix Therapeutics

$42.93 /

+0.31 (+0.73%)

, FULC

Fulcrum Therapeutics

$12.00 /

+0.56 (+4.90%)

, NCNA

NuCana

$4.52 /

+0.02 (+0.44%)

, MDT

Medtronic

$112.24 /

-1.49 (-1.31%)

32nd Annual Virtual…

32nd Annual Virtual Healthcare Conference will be held on November 30-December 3.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$146.00 /

-3.175 (-2.13%)

XNCR Xencor
$41.36 /

-0.97 (-2.29%)

VCRA Vocera
$34.64 /

+0.87 (+2.58%)

OTIC Otonomy
$4.81 /

+0.345 (+7.73%)

OMCL Omnicell
$107.17 /

+2.4 (+2.29%)

NRIX Nurix Therapeutics
$42.93 /

+0.31 (+0.73%)

NCNA NuCana
$4.52 /

+0.02 (+0.44%)

MDT Medtronic
$112.24 /

-1.49 (-1.31%)

MASI Masimo
$253.27 /

-1.38 (-0.54%)

IMV IMV Inc.
$3.63 /

-0.23 (-5.96%)

ICPT Intercept
$35.69 /

+0.21 (+0.59%)

FULC Fulcrum Therapeutics
$12.00 /

+0.56 (+4.90%)

BBI Brickell Biotech
$0.64 /

-0.0289 (-4.31%)

APTX Aptinyx
$3.55 /

-0.425 (-10.71%)

AMRN Amarin
$4.92 /

-0.04 (-0.81%)

ALT Altimmune
$13.82 /

+1.63 (+13.37%)

ALPN Alpine Immune Sciences
$9.64 /

-0.305 (-3.07%)

ALLO Allogene Therapeutics
$31.91 /

+0.9 (+2.90%)

ALGN Align Technology
$500.52 /

+18.81 (+3.90%)

ALBO Albireo Pharma
$37.93 /

+0.72 (+1.93%)

ABMD Abiomed
$268.45 /

-5.95 (-2.17%)

ABMD Abiomed
$268.45 /

-5.95 (-2.17%)

10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
07/13/20 OTR Global
Abiomed upgraded to Positive from Mixed at OTR Global
05/28/20 SVB Leerink
Abiomed price target raised to $225 from $195 at SVB Leerink
ALBO Albireo Pharma
$37.93 /

+0.72 (+1.93%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
ALGN Align Technology
$500.52 /

+18.81 (+3.90%)

11/24/20 SVB Leerink
Align Technology price target raised to $520 from $460 at SVB Leerink
11/24/20 Credit Suisse
Align Technology price target raised to $515 from $432 at Credit Suisse
11/24/20 Goldman Sachs
Align Technology price target raised to $535 from $472 at Goldman Sachs
11/24/20 Baird
Align Technology price target raised to $530 from $450 at Baird
ALLO Allogene Therapeutics
$31.91 /

+0.9 (+2.90%)

11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
11/04/20 Oppenheimer
Allogene weakness after abstract a buying opportunity, says Oppenheimer
11/04/20 Roth Capital
Question of safety with Allogene's Allo-CARs may be premature, says Roth Capital
ALPN Alpine Immune Sciences
$9.64 /

-0.305 (-3.07%)

08/26/20 Cowen
Alpine Immune Sciences initiated with an Outperform at Cowen
08/11/20 Piper Sandler
Alpine Immune Sciences price target lowered to $18 from $21 at Piper Sandler
06/19/20 Wedbush
Alpine Immune price target raised to $22 from $10 at Wedbush
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ALT Altimmune
$13.82 /

+1.63 (+13.37%)

11/25/20 Piper Sandler
Phase 1 safety/immunogenicity to set Altimmune AdCOVID apart, says Piper Sandler
11/24/20 Piper Sandler
Astra vaccine results 'de-risking' for Altimmune, says Piper Sandler
11/12/20 B. Riley Securities
Altimmune selloff on vaccine news overblown, says B. Riley Securities
10/12/20 Piper Sandler
Piper sees AdCOVID pre-clinical data helping benchmark Altimmune COVID program
AMRN Amarin
$4.92 /

-0.04 (-0.81%)

12/01/20 Goldman Sachs
Amarin faces 'generally high bar' in suit against Hikma, says Goldman Sachs
11/20/20 Piper Sandler
Piper keeps $19 target on Amarin, sees China as potential 'lucrative' market
11/05/20 Piper Sandler
Piper remains bullish about Vascepa after Amarin Q3 report, Hikma announcement
10/26/20 Piper Sandler
Piper says Amarin presentations add 'layers of compelling evidence' for Vascepa
APTX Aptinyx
$3.55 /

-0.425 (-10.71%)

11/19/20 H.C. Wainwright
Aptinyx price target raised to $8 from $7 at H.C. Wainwright
11/12/20 Piper Sandler
Aptinyx pipeline catalysts on track, says Piper Sandler
10/28/20 Cantor Fitzgerald
Aptinyx price target raised to $12 from $9 at Cantor Fitzgerald
10/27/20 Piper Sandler
Aptinyx initiated with an Overweight at Piper Sandler
BBI Brickell Biotech
$0.64 /

-0.0289 (-4.31%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
MASI Masimo
$253.27 /

-1.38 (-0.54%)

11/02/20 Piper Sandler
Masimo acquisition brings 'solid opportunity,' says Piper Sandler
10/28/20 Piper Sandler
Masimo price target raised to $280 from $250 at Piper Sandler
10/06/20 Piper Sandler
Better than expected sensor utilization drove Masimo upside, says Piper Sandler
09/01/20 Baird
Masimo initiated with an Outperform at Baird
ZBH Zimmer Biomet
$146.00 /

-3.175 (-2.13%)

11/09/20 SVB Leerink
Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
11/09/20 Credit Suisse
Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
11/09/20 Baird
Zimmer Biomet valuation discount to peers hard to justify, says at Baird
11/09/20 Oppenheimer
Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
XNCR Xencor
$41.36 /

-0.97 (-2.29%)

11/16/20 Cantor Fitzgerald
Xencor price target raised to $56 from $40 at Cantor Fitzgerald
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
VCRA Vocera
$34.64 /

+0.87 (+2.58%)

11/10/20 Stephens
Vocera initiated with an Overweight at Stephens
10/30/20 Piper Sandler
Vocera price target raised to $41 from $28 at Piper Sandler
07/28/20
Fly Intel: Top five analyst upgrades
07/28/20 Craig-Hallum
Vocera upgraded to Buy from Hold at Craig-Hallum
ICPT Intercept
$35.69 /

+0.21 (+0.59%)

11/30/20 Citi
Intercept risk/reward favorable after pullback, says Citi
11/30/20 Citi
CymaBay price target raised to $10 from $9 at Citi
11/20/20 B. Riley Securities
Intercept price target lowered to $74 from $97 at B. Riley Securities
11/16/20 RBC Capital
RBC says new AE data on Ocaliva's Intercept 'does not reassure'
IMV IMV Inc.
$3.63 /

-0.23 (-5.96%)

07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
OTIC Otonomy
$4.81 /

+0.345 (+7.73%)

11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
07/07/20 H.C. Wainwright
Otonomy price target raised to $9 from $8 at H.C. Wainwright
06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
OMCL Omnicell
$107.17 /

+2.4 (+2.29%)

10/28/20 Craig-Hallum
Omnicell price target raised to $100 from $85 at Craig-Hallum
10/28/20 Wells Fargo
Omnicell price target raised to $84 from $74 at Wells Fargo
10/28/20 Cantor Fitzgerald
Omnicell price target raised to $95 from $90 at Cantor Fitzgerald
10/28/20 Piper Sandler
Omnicell price target raised to $86 from $70 at Piper Sandler
NRIX Nurix Therapeutics
$42.93 /

+0.31 (+0.73%)

11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
11/19/20 Baird
Baird starts Nurix Therapeutics with Outperform, $40 price target
11/18/20 Baird
Nurix Therapeutics initiated with an Outperform at Baird
08/18/20
Fly Intel: Top five analyst initiations
FULC Fulcrum Therapeutics
$12.00 /

+0.56 (+4.90%)

10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
08/12/20 Morgan Stanley
Fulcrum Therapeutics downgraded at Morgan Stanley, price target slashed to $11
NCNA NuCana
$4.52 /

+0.02 (+0.44%)

12/01/20 H.C. Wainwright
NuCana price target lowered to $10 from $15 at H.C. Wainwright
11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
10/22/20 Truist
NuCana initiated with a Buy at Truist
MDT Medtronic
$112.24 /

-1.49 (-1.31%)

11/25/20 SVB Leerink
Medtronic price target raised to $123 from $111 at SVB Leerink
11/25/20 Wells Fargo
Medtronic price target raised to $135 from $127 at Wells Fargo
11/25/20 Credit Suisse
Medtronic price target raised to $126 from $118 at Credit Suisse
11/25/20 Oppenheimer
Medtronic price target raised to $128 from $122 at Oppenheimer
ZBH Zimmer Biomet
$146.00 /

-3.175 (-2.13%)

XNCR Xencor
$41.36 /

-0.97 (-2.29%)

VCRA Vocera
$34.64 /

+0.87 (+2.58%)

OTIC Otonomy
$4.81 /

+0.345 (+7.73%)

OMCL Omnicell
$107.17 /

+2.4 (+2.29%)

NRIX Nurix Therapeutics
$42.93 /

+0.31 (+0.73%)

NCNA NuCana
$4.52 /

+0.02 (+0.44%)

MDT Medtronic
$112.24 /

-1.49 (-1.31%)

MASI Masimo
$253.27 /

-1.38 (-0.54%)

ICPT Intercept
$35.69 /

+0.21 (+0.59%)

FULC Fulcrum Therapeutics
$12.00 /

+0.56 (+4.90%)

APTX Aptinyx
$3.55 /

-0.425 (-10.71%)

AMRN Amarin
$4.92 /

-0.04 (-0.81%)

ALPN Alpine Immune Sciences
$9.64 /

-0.305 (-3.07%)

ALLO Allogene Therapeutics
$31.91 /

+0.9 (+2.90%)

ALGN Align Technology
$500.52 /

+18.81 (+3.90%)

ALBO Albireo Pharma
$37.93 /

+0.72 (+1.93%)

ABMD Abiomed
$268.45 /

-5.95 (-2.17%)

  • 23
    Oct
  • 22
    Oct
  • 17
    Sep
  • 10
    Sep
  • 18
    Aug
  • 24
    Jul
  • 14
    Jul
  • 09
    Jul
  • 18
    Jun
  • 02
    Jun
  • 30
    Jan
  • 10
    Jan
MDT Medtronic
$112.24 /

-1.49 (-1.31%)

ICPT Intercept
$35.69 /

+0.21 (+0.59%)

AMRN Amarin
$4.92 /

-0.04 (-0.81%)

VCRA Vocera
$34.64 /

+0.87 (+2.58%)

OTIC Otonomy
$4.81 /

+0.345 (+7.73%)

NRIX Nurix Therapeutics
$42.93 /

+0.31 (+0.73%)

NCNA NuCana
$4.52 /

+0.02 (+0.44%)

MDT Medtronic
$112.24 /

-1.49 (-1.31%)

MASI Masimo
$253.27 /

-1.38 (-0.54%)

ICPT Intercept
$35.69 /

+0.21 (+0.59%)

FULC Fulcrum Therapeutics
$12.00 /

+0.56 (+4.90%)

APTX Aptinyx
$3.55 /

-0.425 (-10.71%)

AMRN Amarin
$4.92 /

-0.04 (-0.81%)

ALT Altimmune
$13.82 /

+1.63 (+13.37%)

ALLO Allogene Therapeutics
$31.91 /

+0.9 (+2.90%)

ALGN Align Technology
$500.52 /

+18.81 (+3.90%)

ALBO Albireo Pharma
$37.93 /

+0.72 (+1.93%)

MDT Medtronic
$112.24 /

-1.49 (-1.31%)

IMV IMV Inc.
$3.63 /

-0.23 (-5.96%)

APTX Aptinyx
$3.55 /

-0.425 (-10.71%)

AMRN Amarin
$4.92 /

-0.04 (-0.81%)

ALT Altimmune
$13.82 /

+1.63 (+13.37%)

ALGN Align Technology
$500.52 /

+18.81 (+3.90%)

Yesterday
Hot Stocks
Hologic receives FDA clearance for Genius AI Detection technology » 08:12
12/01/20
12/01
08:12
12/01/20
08:12
HOLX

Hologic

$69.16 /

-0.33 (-0.47%)

Hologic announced FDA…

Hologic announced FDA clearance and commercial availability of the company's Genius AI Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.

ShowHide Related Items >><<
HOLX Hologic
$69.16 /

-0.33 (-0.47%)

HOLX Hologic
$69.16 /

-0.33 (-0.47%)

11/20/20
Fly Intel: Top five analyst downgrades
11/20/20 Needham
Needham downgrades Hologic ahead of COVID-19 testing decline
11/20/20 Needham
Hologic downgraded to Hold from Buy at Needham
11/05/20 SVB Leerink
Hologic price target raised to $94 from $80 at SVB Leerink
HOLX Hologic
$69.16 /

-0.33 (-0.47%)

HOLX Hologic
$69.16 /

-0.33 (-0.47%)

HOLX Hologic
$69.16 /

-0.33 (-0.47%)

Hot Stocks
Boston Scientific to sell BTG Specialty Pharmaceuticals business for $800M » 06:33
12/01/20
12/01
06:33
12/01/20
06:33
BSX

Boston Scientific

$33.15 /

-0.545 (-1.62%)

Boston Scientific…

Boston Scientific announced that it has entered into a definitive agreement with Stark International Lux and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800M in cash. SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a portfolio of prescription medicines focused on rare and life-threatening diseases. The BTG Specialty Pharmaceuticals business develops, manufactures and commercializes life-saving antidotes used in hospitals and emergency care settings, including CroFab, DigiFab and Voraxaze. The three franchises are expected to generate approximately $210M in revenue for FY20. The agreement includes the transfer of five facilities and approximately 280 employees globally. The transaction is expected to close in the first half of 2021, subject to customary regulatory approvals and other closing conditions.

ShowHide Related Items >><<
BSX Boston Scientific
$33.15 /

-0.545 (-1.62%)

BSX Boston Scientific
$33.15 /

-0.545 (-1.62%)

11/18/20 Truist
Boston Scientific price target lowered to $44 from $47 at Truist
11/18/20 Wells Fargo
Medtronic price target raised to $127 from $118 at Wells Fargo
11/18/20 Citi
Boston Scientific price target lowered to $43 from $46 at Citi
11/17/20 Stifel
Boston TAVR setback 'disappointing' given once-high LOTUS hopes, says Stifel
BSX Boston Scientific
$33.15 /

-0.545 (-1.62%)

  • 22
    May
BSX Boston Scientific
$33.15 /

-0.545 (-1.62%)

BSX Boston Scientific
$33.15 /

-0.545 (-1.62%)

BSX Boston Scientific
$33.15 /

-0.545 (-1.62%)

Conference/Events
Piper Sandler to hold a virtual conference » 04:55
12/01/20
12/01
04:55
12/01/20
04:55
ABMD

Abiomed

$274.40 /

+2.72 (+1.00%)

, ALBO

Albireo Pharma

$37.16 /

+0.91 (+2.51%)

, ALGN

Align Technology

$481.71 /

+6.94 (+1.46%)

, ALLO

Allogene Therapeutics

$31.01 /

-0.37 (-1.18%)

, ALPN

Alpine Immune Sciences

$9.94 /

+0.1 (+1.02%)

, ALT

Altimmune

$12.22 /

+1.77 (+16.94%)

, AMRN

Amarin

$4.96 /

+0.355 (+7.72%)

, APTX

Aptinyx

$3.97 /

+0.16 (+4.20%)

, BBI

Brickell Biotech

$0.67 /

+0.0099 (+1.50%)

, MASI

Masimo

$254.65 /

+0.36 (+0.14%)

, ZBH

Zimmer Biomet

$149.21 /

-0.79 (-0.53%)

, XNCR

Xencor

$42.38 /

-0.37 (-0.87%)

, VCRA

Vocera

$33.84 /

-0.3098 (-0.91%)

, ICPT

Intercept

$35.47 /

-1.99 (-5.31%)

, IMV

IMV Inc.

$3.86 /

+0.28 (+7.82%)

, OTIC

Otonomy

$4.48 /

-0.04 (-0.88%)

, OMCL

Omnicell

$104.77 /

-1.77 (-1.66%)

, NRIX

Nurix Therapeutics

$42.45 /

+2.84 (+7.17%)

, FULC

Fulcrum Therapeutics

$11.42 /

-0.06 (-0.52%)

, NCNA

NuCana

$4.49 /

-0.01 (-0.22%)

, MDT

Medtronic

$113.73 /

-0.88 (-0.77%)

32nd Annual Virtual…

32nd Annual Virtual Healthcare Conference will be held on November 30-December 3.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$149.21 /

-0.79 (-0.53%)

XNCR Xencor
$42.38 /

-0.37 (-0.87%)

VCRA Vocera
$33.84 /

-0.3098 (-0.91%)

OTIC Otonomy
$4.48 /

-0.04 (-0.88%)

OMCL Omnicell
$104.77 /

-1.77 (-1.66%)

NRIX Nurix Therapeutics
$42.45 /

+2.84 (+7.17%)

NCNA NuCana
$4.49 /

-0.01 (-0.22%)

MDT Medtronic
$113.73 /

-0.88 (-0.77%)

MASI Masimo
$254.65 /

+0.36 (+0.14%)

IMV IMV Inc.
$3.86 /

+0.28 (+7.82%)

ICPT Intercept
$35.47 /

-1.99 (-5.31%)

FULC Fulcrum Therapeutics
$11.42 /

-0.06 (-0.52%)

BBI Brickell Biotech
$0.67 /

+0.0099 (+1.50%)

APTX Aptinyx
$3.97 /

+0.16 (+4.20%)

AMRN Amarin
$4.96 /

+0.355 (+7.72%)

ALT Altimmune
$12.22 /

+1.77 (+16.94%)

ALPN Alpine Immune Sciences
$9.94 /

+0.1 (+1.02%)

ALLO Allogene Therapeutics
$31.01 /

-0.37 (-1.18%)

ALGN Align Technology
$481.71 /

+6.94 (+1.46%)

ALBO Albireo Pharma
$37.16 /

+0.91 (+2.51%)

ABMD Abiomed
$274.40 /

+2.72 (+1.00%)

ABMD Abiomed
$274.40 /

+2.72 (+1.00%)

10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
07/13/20 OTR Global
Abiomed upgraded to Positive from Mixed at OTR Global
05/28/20 SVB Leerink
Abiomed price target raised to $225 from $195 at SVB Leerink
ALBO Albireo Pharma
$37.16 /

+0.91 (+2.51%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
ALGN Align Technology
$481.71 /

+6.94 (+1.46%)

11/24/20 SVB Leerink
Align Technology price target raised to $520 from $460 at SVB Leerink
11/24/20 Credit Suisse
Align Technology price target raised to $515 from $432 at Credit Suisse
11/24/20 Goldman Sachs
Align Technology price target raised to $535 from $472 at Goldman Sachs
11/24/20 Baird
Align Technology price target raised to $530 from $450 at Baird
ALLO Allogene Therapeutics
$31.01 /

-0.37 (-1.18%)

11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
11/04/20 Oppenheimer
Allogene weakness after abstract a buying opportunity, says Oppenheimer
11/04/20 Roth Capital
Question of safety with Allogene's Allo-CARs may be premature, says Roth Capital
ALPN Alpine Immune Sciences
$9.94 /

+0.1 (+1.02%)

08/26/20 Cowen
Alpine Immune Sciences initiated with an Outperform at Cowen
08/11/20 Piper Sandler
Alpine Immune Sciences price target lowered to $18 from $21 at Piper Sandler
06/19/20 Wedbush
Alpine Immune price target raised to $22 from $10 at Wedbush
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ALT Altimmune
$12.22 /

+1.77 (+16.94%)

11/25/20 Piper Sandler
Phase 1 safety/immunogenicity to set Altimmune AdCOVID apart, says Piper Sandler
11/24/20 Piper Sandler
Astra vaccine results 'de-risking' for Altimmune, says Piper Sandler
11/12/20 B. Riley Securities
Altimmune selloff on vaccine news overblown, says B. Riley Securities
10/12/20 Piper Sandler
Piper sees AdCOVID pre-clinical data helping benchmark Altimmune COVID program
AMRN Amarin
$4.96 /

+0.355 (+7.72%)

11/20/20 Piper Sandler
Piper keeps $19 target on Amarin, sees China as potential 'lucrative' market
11/05/20 Piper Sandler
Piper remains bullish about Vascepa after Amarin Q3 report, Hikma announcement
10/26/20 Piper Sandler
Piper says Amarin presentations add 'layers of compelling evidence' for Vascepa
10/15/20 Piper Sandler
Analysis of Amarin's Vascepa to drive increased market share, says Piper Sandler
APTX Aptinyx
$3.97 /

+0.16 (+4.20%)

11/19/20 H.C. Wainwright
Aptinyx price target raised to $8 from $7 at H.C. Wainwright
11/12/20 Piper Sandler
Aptinyx pipeline catalysts on track, says Piper Sandler
10/28/20 Cantor Fitzgerald
Aptinyx price target raised to $12 from $9 at Cantor Fitzgerald
10/27/20 Piper Sandler
Aptinyx initiated with an Overweight at Piper Sandler
BBI Brickell Biotech
$0.67 /

+0.0099 (+1.50%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
MASI Masimo
$254.65 /

+0.36 (+0.14%)

11/02/20 Piper Sandler
Masimo acquisition brings 'solid opportunity,' says Piper Sandler
10/28/20 Piper Sandler
Masimo price target raised to $280 from $250 at Piper Sandler
10/06/20 Piper Sandler
Better than expected sensor utilization drove Masimo upside, says Piper Sandler
09/01/20 Baird
Masimo initiated with an Outperform at Baird
ZBH Zimmer Biomet
$149.21 /

-0.79 (-0.53%)

11/09/20 SVB Leerink
Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
11/09/20 Credit Suisse
Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
11/09/20 Baird
Zimmer Biomet valuation discount to peers hard to justify, says at Baird
11/09/20 Oppenheimer
Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
XNCR Xencor
$42.38 /

-0.37 (-0.87%)

11/16/20 Cantor Fitzgerald
Xencor price target raised to $56 from $40 at Cantor Fitzgerald
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
VCRA Vocera
$33.84 /

-0.3098 (-0.91%)

11/10/20 Stephens
Vocera initiated with an Overweight at Stephens
10/30/20 Piper Sandler
Vocera price target raised to $41 from $28 at Piper Sandler
07/28/20
Fly Intel: Top five analyst upgrades
07/28/20 Craig-Hallum
Vocera upgraded to Buy from Hold at Craig-Hallum
ICPT Intercept
$35.47 /

-1.99 (-5.31%)

11/30/20 Citi
Intercept risk/reward favorable after pullback, says Citi
11/30/20 Citi
CymaBay price target raised to $10 from $9 at Citi
11/20/20 B. Riley Securities
Intercept price target lowered to $74 from $97 at B. Riley Securities
11/16/20 RBC Capital
RBC says new AE data on Ocaliva's Intercept 'does not reassure'
IMV IMV Inc.
$3.86 /

+0.28 (+7.82%)

07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
OTIC Otonomy
$4.48 /

-0.04 (-0.88%)

11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
07/07/20 H.C. Wainwright
Otonomy price target raised to $9 from $8 at H.C. Wainwright
06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
OMCL Omnicell
$104.77 /

-1.77 (-1.66%)

10/28/20 Craig-Hallum
Omnicell price target raised to $100 from $85 at Craig-Hallum
10/28/20 Wells Fargo
Omnicell price target raised to $84 from $74 at Wells Fargo
10/28/20 Cantor Fitzgerald
Omnicell price target raised to $95 from $90 at Cantor Fitzgerald
10/28/20 Piper Sandler
Omnicell price target raised to $86 from $70 at Piper Sandler
NRIX Nurix Therapeutics
$42.45 /

+2.84 (+7.17%)

11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
11/19/20 Baird
Baird starts Nurix Therapeutics with Outperform, $40 price target
11/18/20 Baird
Nurix Therapeutics initiated with an Outperform at Baird
08/18/20
Fly Intel: Top five analyst initiations
FULC Fulcrum Therapeutics
$11.42 /

-0.06 (-0.52%)

10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
08/12/20 Morgan Stanley
Fulcrum Therapeutics downgraded at Morgan Stanley, price target slashed to $11
NCNA NuCana
$4.49 /

-0.01 (-0.22%)

11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
10/22/20 Truist
NuCana initiated with a Buy at Truist
08/21/20 Piper Sandler
NuCana price target raised to $17 from $15 at Piper Sandler
MDT Medtronic
$113.73 /

-0.88 (-0.77%)

11/25/20 SVB Leerink
Medtronic price target raised to $123 from $111 at SVB Leerink
11/25/20 Wells Fargo
Medtronic price target raised to $135 from $127 at Wells Fargo
11/25/20 Credit Suisse
Medtronic price target raised to $126 from $118 at Credit Suisse
11/25/20 Oppenheimer
Medtronic price target raised to $128 from $122 at Oppenheimer
ZBH Zimmer Biomet
$149.21 /

-0.79 (-0.53%)

XNCR Xencor
$42.38 /

-0.37 (-0.87%)

VCRA Vocera
$33.84 /

-0.3098 (-0.91%)

OTIC Otonomy
$4.48 /

-0.04 (-0.88%)

OMCL Omnicell
$104.77 /

-1.77 (-1.66%)

NRIX Nurix Therapeutics
$42.45 /

+2.84 (+7.17%)

NCNA NuCana
$4.49 /

-0.01 (-0.22%)

MDT Medtronic
$113.73 /

-0.88 (-0.77%)

MASI Masimo
$254.65 /

+0.36 (+0.14%)

ICPT Intercept
$35.47 /

-1.99 (-5.31%)

FULC Fulcrum Therapeutics
$11.42 /

-0.06 (-0.52%)

APTX Aptinyx
$3.97 /

+0.16 (+4.20%)

AMRN Amarin
$4.96 /

+0.355 (+7.72%)

ALPN Alpine Immune Sciences
$9.94 /

+0.1 (+1.02%)

ALLO Allogene Therapeutics
$31.01 /

-0.37 (-1.18%)

ALGN Align Technology
$481.71 /

+6.94 (+1.46%)

ALBO Albireo Pharma
$37.16 /

+0.91 (+2.51%)

ABMD Abiomed
$274.40 /

+2.72 (+1.00%)

  • 23
    Oct
  • 22
    Oct
  • 17
    Sep
  • 10
    Sep
  • 18
    Aug
  • 24
    Jul
  • 14
    Jul
  • 09
    Jul
  • 18
    Jun
  • 02
    Jun
  • 30
    Jan
  • 10
    Jan
MDT Medtronic
$113.73 /

-0.88 (-0.77%)

ICPT Intercept
$35.47 /

-1.99 (-5.31%)

AMRN Amarin
$4.96 /

+0.355 (+7.72%)

VCRA Vocera
$33.84 /

-0.3098 (-0.91%)

OTIC Otonomy
$4.48 /

-0.04 (-0.88%)

NRIX Nurix Therapeutics
$42.45 /

+2.84 (+7.17%)

NCNA NuCana
$4.49 /

-0.01 (-0.22%)

MDT Medtronic
$113.73 /

-0.88 (-0.77%)

MASI Masimo
$254.65 /

+0.36 (+0.14%)

ICPT Intercept
$35.47 /

-1.99 (-5.31%)

FULC Fulcrum Therapeutics
$11.42 /

-0.06 (-0.52%)

APTX Aptinyx
$3.97 /

+0.16 (+4.20%)

AMRN Amarin
$4.96 /

+0.355 (+7.72%)

ALT Altimmune
$12.22 /

+1.77 (+16.94%)

ALLO Allogene Therapeutics
$31.01 /

-0.37 (-1.18%)

ALGN Align Technology
$481.71 /

+6.94 (+1.46%)

ALBO Albireo Pharma
$37.16 /

+0.91 (+2.51%)

MDT Medtronic
$113.73 /

-0.88 (-0.77%)

IMV IMV Inc.
$3.86 /

+0.28 (+7.82%)

APTX Aptinyx
$3.97 /

+0.16 (+4.20%)

AMRN Amarin
$4.96 /

+0.355 (+7.72%)

ALT Altimmune
$12.22 /

+1.77 (+16.94%)

ALGN Align Technology
$481.71 /

+6.94 (+1.46%)

Monday
Conference/Events
Piper Sandler to hold a virtual conference » 08:46
11/30/20
11/30
08:46
11/30/20
08:46
ABMD

Abiomed

$271.70 /

+8.02 (+3.04%)

, ALBO

Albireo Pharma

$36.44 /

-0.53 (-1.43%)

, ALGN

Align Technology

$475.12 /

+0.91 (+0.19%)

, ALLO

Allogene Therapeutics

$31.40 /

-0.355 (-1.12%)

, ALPN

Alpine Immune Sciences

$9.84 /

+0.59 (+6.38%)

, ALT

Altimmune

$10.60 /

+0.55 (+5.47%)

, AMRN

Amarin

$4.63 /

+0.035 (+0.76%)

, APTX

Aptinyx

$3.84 /

+0.41 (+11.95%)

, BBI

Brickell Biotech

$0.68 /

+0.0273 (+4.18%)

, MASI

Masimo

$254.28 /

+8.41 (+3.42%)

, ZBH

Zimmer Biomet

$150.10 /

+0.64 (+0.43%)

, XNCR

Xencor

$42.75 /

+1.695 (+4.13%)

, VCRA

Vocera

$34.05 /

+0.75 (+2.25%)

, ICPT

Intercept

$37.29 /

-0.01 (-0.03%)

, IMV

IMV Inc.

$3.58 /

+0.13 (+3.77%)

, OTIC

Otonomy

$4.50 /

+0.22 (+5.14%)

, OMCL

Omnicell

$106.54 /

-0.32 (-0.30%)

, NRIX

Nurix Therapeutics

$39.15 /

+0.7 (+1.82%)

, FULC

Fulcrum Therapeutics

$11.72 /

+0.42 (+3.72%)

, NCNA

NuCana

$4.50 /

+0.04 (+0.90%)

, MDT

Medtronic

$114.69 /

+1.4 (+1.24%)

32nd Annual Virtual…

32nd Annual Virtual Healthcare Conference will be held on November 30-December 3.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$150.10 /

+0.64 (+0.43%)

XNCR Xencor
$42.75 /

+1.695 (+4.13%)

VCRA Vocera
$34.05 /

+0.75 (+2.25%)

OTIC Otonomy
$4.50 /

+0.22 (+5.14%)

OMCL Omnicell
$106.54 /

-0.32 (-0.30%)

NRIX Nurix Therapeutics
$39.15 /

+0.7 (+1.82%)

MDT Medtronic
$114.69 /

+1.4 (+1.24%)

MASI Masimo
$254.28 /

+8.41 (+3.42%)

IMV IMV Inc.
$3.58 /

+0.13 (+3.77%)

ICPT Intercept
$37.29 /

-0.01 (-0.03%)

FULC Fulcrum Therapeutics
$11.72 /

+0.42 (+3.72%)

BBI Brickell Biotech
$0.68 /

+0.0273 (+4.18%)

APTX Aptinyx
$3.84 /

+0.41 (+11.95%)

AMRN Amarin
$4.63 /

+0.035 (+0.76%)

ALT Altimmune
$10.60 /

+0.55 (+5.47%)

ALPN Alpine Immune Sciences
$9.84 /

+0.59 (+6.38%)

ALLO Allogene Therapeutics
$31.40 /

-0.355 (-1.12%)

ALGN Align Technology
$475.12 /

+0.91 (+0.19%)

ALBO Albireo Pharma
$36.44 /

-0.53 (-1.43%)

ABMD Abiomed
$271.70 /

+8.02 (+3.04%)

ABMD Abiomed
$271.70 /

+8.02 (+3.04%)

10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
07/13/20 OTR Global
Abiomed upgraded to Positive from Mixed at OTR Global
05/28/20 SVB Leerink
Abiomed price target raised to $225 from $195 at SVB Leerink
ALBO Albireo Pharma
$36.44 /

-0.53 (-1.43%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
ALGN Align Technology
$475.12 /

+0.91 (+0.19%)

11/24/20 SVB Leerink
Align Technology price target raised to $520 from $460 at SVB Leerink
11/24/20 Credit Suisse
Align Technology price target raised to $515 from $432 at Credit Suisse
11/24/20 Goldman Sachs
Align Technology price target raised to $535 from $472 at Goldman Sachs
11/24/20 Baird
Align Technology price target raised to $530 from $450 at Baird
ALLO Allogene Therapeutics
$31.40 /

-0.355 (-1.12%)

11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
11/04/20 Oppenheimer
Allogene weakness after abstract a buying opportunity, says Oppenheimer
11/04/20 Roth Capital
Question of safety with Allogene's Allo-CARs may be premature, says Roth Capital
ALPN Alpine Immune Sciences
$9.84 /

+0.59 (+6.38%)

08/26/20 Cowen
Alpine Immune Sciences initiated with an Outperform at Cowen
08/11/20 Piper Sandler
Alpine Immune Sciences price target lowered to $18 from $21 at Piper Sandler
06/19/20 Wedbush
Alpine Immune price target raised to $22 from $10 at Wedbush
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ALT Altimmune
$10.60 /

+0.55 (+5.47%)

11/25/20 Piper Sandler
Phase 1 safety/immunogenicity to set Altimmune AdCOVID apart, says Piper Sandler
11/24/20 Piper Sandler
Astra vaccine results 'de-risking' for Altimmune, says Piper Sandler
11/12/20 B. Riley Securities
Altimmune selloff on vaccine news overblown, says B. Riley Securities
10/12/20 Piper Sandler
Piper sees AdCOVID pre-clinical data helping benchmark Altimmune COVID program
AMRN Amarin
$4.63 /

+0.035 (+0.76%)

11/20/20 Piper Sandler
Piper keeps $19 target on Amarin, sees China as potential 'lucrative' market
11/05/20 Piper Sandler
Piper remains bullish about Vascepa after Amarin Q3 report, Hikma announcement
10/26/20 Piper Sandler
Piper says Amarin presentations add 'layers of compelling evidence' for Vascepa
10/15/20 Piper Sandler
Analysis of Amarin's Vascepa to drive increased market share, says Piper Sandler
APTX Aptinyx
$3.84 /

+0.41 (+11.95%)

11/19/20 H.C. Wainwright
Aptinyx price target raised to $8 from $7 at H.C. Wainwright
11/12/20 Piper Sandler
Aptinyx pipeline catalysts on track, says Piper Sandler
10/28/20 Cantor Fitzgerald
Aptinyx price target raised to $12 from $9 at Cantor Fitzgerald
10/27/20 Piper Sandler
Aptinyx initiated with an Overweight at Piper Sandler
BBI Brickell Biotech
$0.68 /

+0.0273 (+4.18%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
MASI Masimo
$254.28 /

+8.41 (+3.42%)

11/02/20 Piper Sandler
Masimo acquisition brings 'solid opportunity,' says Piper Sandler
10/28/20 Piper Sandler
Masimo price target raised to $280 from $250 at Piper Sandler
10/06/20 Piper Sandler
Better than expected sensor utilization drove Masimo upside, says Piper Sandler
09/01/20 Baird
Masimo initiated with an Outperform at Baird
ZBH Zimmer Biomet
$150.10 /

+0.64 (+0.43%)

11/09/20 SVB Leerink
Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
11/09/20 Credit Suisse
Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
11/09/20 Baird
Zimmer Biomet valuation discount to peers hard to justify, says at Baird
11/09/20 Oppenheimer
Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
XNCR Xencor
$42.75 /

+1.695 (+4.13%)

11/16/20 Cantor Fitzgerald
Xencor price target raised to $56 from $40 at Cantor Fitzgerald
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
VCRA Vocera
$34.05 /

+0.75 (+2.25%)

11/10/20 Stephens
Vocera initiated with an Overweight at Stephens
10/30/20 Piper Sandler
Vocera price target raised to $41 from $28 at Piper Sandler
07/28/20
Fly Intel: Top five analyst upgrades
07/28/20 Craig-Hallum
Vocera upgraded to Buy from Hold at Craig-Hallum
ICPT Intercept
$37.29 /

-0.01 (-0.03%)

11/30/20 Citi
Intercept risk/reward favorable after pullback, says Citi
11/30/20 Citi
CymaBay price target raised to $10 from $9 at Citi
11/20/20 B. Riley Securities
Intercept price target lowered to $74 from $97 at B. Riley Securities
11/16/20 RBC Capital
RBC says new AE data on Ocaliva's Intercept 'does not reassure'
IMV IMV Inc.
$3.58 /

+0.13 (+3.77%)

07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
OTIC Otonomy
$4.50 /

+0.22 (+5.14%)

11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
07/07/20 H.C. Wainwright
Otonomy price target raised to $9 from $8 at H.C. Wainwright
06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
OMCL Omnicell
$106.54 /

-0.32 (-0.30%)

10/28/20 Craig-Hallum
Omnicell price target raised to $100 from $85 at Craig-Hallum
10/28/20 Wells Fargo
Omnicell price target raised to $84 from $74 at Wells Fargo
10/28/20 Cantor Fitzgerald
Omnicell price target raised to $95 from $90 at Cantor Fitzgerald
10/28/20 Piper Sandler
Omnicell price target raised to $86 from $70 at Piper Sandler
NRIX Nurix Therapeutics
$39.15 /

+0.7 (+1.82%)

11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
11/19/20 Baird
Baird starts Nurix Therapeutics with Outperform, $40 price target
11/18/20 Baird
Nurix Therapeutics initiated with an Outperform at Baird
08/18/20
Fly Intel: Top five analyst initiations
FULC Fulcrum Therapeutics
$11.72 /

+0.42 (+3.72%)

10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
08/12/20 Morgan Stanley
Fulcrum Therapeutics downgraded at Morgan Stanley, price target slashed to $11
NCNA NuCana
$4.50 /

+0.04 (+0.90%)

11/24/20 H.C. Wainwright
NuCana price target lowered to $15 from $17 at H.C. Wainwright
10/22/20 Truist
NuCana initiated with a Buy at Truist
10/22/20 Truist
NuCana initiated with a Buy at Truist
08/21/20 Piper Sandler
NuCana price target raised to $17 from $15 at Piper Sandler
MDT Medtronic
$114.69 /

+1.4 (+1.24%)

11/25/20 SVB Leerink
Medtronic price target raised to $123 from $111 at SVB Leerink
11/25/20 Wells Fargo
Medtronic price target raised to $135 from $127 at Wells Fargo
11/25/20 Credit Suisse
Medtronic price target raised to $126 from $118 at Credit Suisse
11/25/20 Oppenheimer
Medtronic price target raised to $128 from $122 at Oppenheimer
ZBH Zimmer Biomet
$150.10 /

+0.64 (+0.43%)

XNCR Xencor
$42.75 /

+1.695 (+4.13%)

VCRA Vocera
$34.05 /

+0.75 (+2.25%)

OTIC Otonomy
$4.50 /

+0.22 (+5.14%)

OMCL Omnicell
$106.54 /

-0.32 (-0.30%)

NRIX Nurix Therapeutics
$39.15 /

+0.7 (+1.82%)

NCNA NuCana
$4.50 /

+0.04 (+0.90%)

MDT Medtronic
$114.69 /

+1.4 (+1.24%)

MASI Masimo
$254.28 /

+8.41 (+3.42%)

ICPT Intercept
$37.29 /

-0.01 (-0.03%)

FULC Fulcrum Therapeutics
$11.72 /

+0.42 (+3.72%)

APTX Aptinyx
$3.84 /

+0.41 (+11.95%)

AMRN Amarin
$4.63 /

+0.035 (+0.76%)

ALPN Alpine Immune Sciences
$9.84 /

+0.59 (+6.38%)

ALLO Allogene Therapeutics
$31.40 /

-0.355 (-1.12%)

ALGN Align Technology
$475.12 /

+0.91 (+0.19%)

ALBO Albireo Pharma
$36.44 /

-0.53 (-1.43%)

ABMD Abiomed
$271.70 /

+8.02 (+3.04%)

  • 23
    Oct
  • 22
    Oct
  • 17
    Sep
  • 10
    Sep
  • 18
    Aug
  • 24
    Jul
  • 14
    Jul
  • 09
    Jul
  • 18
    Jun
  • 02
    Jun
  • 30
    Jan
  • 10
    Jan
MDT Medtronic
$114.69 /

+1.4 (+1.24%)

ICPT Intercept
$37.29 /

-0.01 (-0.03%)

AMRN Amarin
$4.63 /

+0.035 (+0.76%)

VCRA Vocera
$34.05 /

+0.75 (+2.25%)

OTIC Otonomy
$4.50 /

+0.22 (+5.14%)

NRIX Nurix Therapeutics
$39.15 /

+0.7 (+1.82%)

NCNA NuCana
$4.50 /

+0.04 (+0.90%)

MDT Medtronic
$114.69 /

+1.4 (+1.24%)

MASI Masimo
$254.28 /

+8.41 (+3.42%)

ICPT Intercept
$37.29 /

-0.01 (-0.03%)

FULC Fulcrum Therapeutics
$11.72 /

+0.42 (+3.72%)

APTX Aptinyx
$3.84 /

+0.41 (+11.95%)

AMRN Amarin
$4.63 /

+0.035 (+0.76%)

ALT Altimmune
$10.60 /

+0.55 (+5.47%)

ALLO Allogene Therapeutics
$31.40 /

-0.355 (-1.12%)

ALGN Align Technology
$475.12 /

+0.91 (+0.19%)

ALBO Albireo Pharma
$36.44 /

-0.53 (-1.43%)

MDT Medtronic
$114.69 /

+1.4 (+1.24%)

IMV IMV Inc.
$3.58 /

+0.13 (+3.77%)

APTX Aptinyx
$3.84 /

+0.41 (+11.95%)

AMRN Amarin
$4.63 /

+0.035 (+0.76%)

ALT Altimmune
$10.60 /

+0.55 (+5.47%)

ALGN Align Technology
$475.12 /

+0.91 (+0.19%)

Recommendations
AbbVie price target raised to $120 from $108 at Morgan Stanley » 07:24
11/30/20
11/30
07:24
11/30/20
07:24
ABBV

AbbVie

$104.85 /

+0.67 (+0.64%)

, SNY

Sanofi

$51.11 /

+0.93 (+1.85%)

, REGN

Regeneron

$512.05 /

+3.01 (+0.59%)

Morgan Stanley analyst…

Morgan Stanley analyst David Risinger raised the firm's price target on AbbVie (ABBV) to $120 from $108 and keeps an Overweight rating on the shares ahead of what he predicts will be a "bullish" Immunology investor day meeting in mid-December. In conjunction with the event, Abbvie may disclose positive data for Rinvoq versus Sanofi (SNY) and Regeneron's (REGN) Dupixent in atopic dermatitis and he expects Abbvie to raise its long-term Skyrizi + Rinvoq projection, Risinger tells investors.

ShowHide Related Items >><<
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

ABBV AbbVie
$104.85 /

+0.67 (+0.64%)

ABBV AbbVie
$104.85 /

+0.67 (+0.64%)

11/24/20 RBC Capital
Enanta price target lowered to $45 from $52 at RBC Capital
11/18/20
Fly Intel: Top five analyst initiations
11/18/20 BMO Capital
AbbVie initiated with an Outperform at BMO Capital
11/12/20 Canaccord
Neurocrine price target lowered to $122 from $145 at Canaccord
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
REGN Regeneron
$512.05 /

+3.01 (+0.59%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

ABBV AbbVie
$104.85 /

+0.67 (+0.64%)

  • 27
    May
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

ABBV AbbVie
$104.85 /

+0.67 (+0.64%)

SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

ABBV AbbVie
$104.85 /

+0.67 (+0.64%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

ABBV AbbVie
$104.85 /

+0.67 (+0.64%)

Hot Stocks
Sanofi, Kiadis Pharma provide update on acquisition offer » 05:47
11/30/20
11/30
05:47
11/30/20
05:47
SNY

Sanofi

$51.11 /

+0.93 (+1.85%)

, KIADF

Kiadis Pharma

$0.00 /

+ (+0.00%)

Sanofi (SNY) and Kiadis…

Sanofi (SNY) and Kiadis Pharma (KIADF) provided a joint update on the offer to be made by Sanofi to acquire Kiadis at an offer price of EUR 5.45 in cash per share. Sanofi and Kiadis said that they are making good progress on the preparations for the offer. Sanofi will submit a request for review and approval of the offer document in relation to the offer with the Netherlands Authority for the Financial Markets. In addition, Sanofi and Kiadis confirm that the process to obtain the required competition clearance for the offer is proceeding. Sanofi and Kiadis anticipate that the offer will close in the first half of 2021.

ShowHide Related Items >><<
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

KIADF Kiadis Pharma
$0.00 /

+ (+0.00%)

SNY Sanofi
$51.11 /

+0.93 (+1.85%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
KIADF Kiadis Pharma
$0.00 /

+ (+0.00%)

11/03/20 Canaccord
Kiadis Pharma downgraded to Hold from Buy at Canaccord
11/02/20 Piper Sandler
Kiadis Pharma downgraded to Neutral from Overweight at Piper Sandler
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/08/20 Piper Sandler
Kiadis Pharma upgraded to Overweight from Neutral at Piper Sandler
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

SNY Sanofi
$51.11 /

+0.93 (+1.85%)

SNY Sanofi
$51.11 /

+0.93 (+1.85%)

Hot Stocks
Regeneron, Sanofi announce EC extension of Dupixent marketing authorization » 05:43
11/30/20
11/30
05:43
11/30/20
05:43
REGN

Regeneron

$512.05 /

+3.01 (+0.59%)

, SNY

Sanofi

$51.11 /

+0.93 (+1.85%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has extended the marketing authorization for Dupixent in the European Union, or EU, to include children six to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients.

ShowHide Related Items >><<
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

  • 27
    May
SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

SNY Sanofi
$51.11 /

+0.93 (+1.85%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

REGN Regeneron
$512.05 /

+3.01 (+0.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.